Merrimack Pharmaceuticals Stock Sank Like a Stone in June

By Markets Fool.com

Image source: Getty Images.

Continue Reading Below

What:Merrimack Pharmaceuticals, an oncology company developing precision medicines,saw its shares drop by nearly 20% last month as a result of the marketwide downturn sparked by the Brexit vote, according to data fromS&P Global Market Intelligence.

MACK data by YCharts.

So what:Merrimack's pronounced slide last month even outpaced the sizable downturn in the iShares Nasdaq Biotechnology ETF :

Continue Reading Below

IBB data by YCharts.

In short, the market seems to be souring on cash-flow-negative operations like Merrimack, regardless of their near- or long-term prospects. Merrimack, for instance, is now trading at about 3 times the 2017 projected revenue from itsadvanced pancreatic cancer drugOnivyde. That's definitely a noteworthy valuation, given that most oncology companies receive ginormous premiums for their lead drugs.

Now what:Onivyde appears set to have a long commercial shelf life, given theparticularlyhigh failure rate for experimental pancreatic cancer drugs in general. So, when the market finally changes its tune toward biotechs, Merrimack should rebound sharply along with the IBB. After all, Merrimack does sport a fairly robust portfolio of clinical-stage anti-cancer drugs, giving it multiple shots on goal in terms of bringing yet another product to market within a few years. And withOnivyde's sales expected to pick up over the next few months, the company should be able to build a respectable cash runway to fund its various clinical activities going forward. All told, Merrimack is arguably a great bargain buy following this latest sell-off in June.

The article Merrimack Pharmaceuticals Stock Sank Like a Stone in June originally appeared on Fool.com.

George Budwell owns shares of iShares NASDAQ Biotechnology Index. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.